CD6-targeted antibody-drug conjugate as a new therapeutic agent for T cell lymphoma

Cancer Statistics, 2021

Rebecca L. Siegel, Kimberly D. Miller, Hannah E. Fuchs et al. · CA A Cancer Journal for Clinicians · 2021 · 17.4K citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes

Journal of Clinical Oncology · 2008 · 2.1K citations

Medicine, Hematology, Pathology +14

cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity

Joseph A. Francisco, Charles G. Cerveny, Damon L. Meyer et al. · Blood · 2003 · 921 citations

Medicine, Medicinal Chemistry, Oncology +11

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice

Elizabeth C. Townsend, Mark A. Murakami, Alexandra Christodoulou et al. · Cancer Cell · 2016 · 304 citations · Full text

Medicine, Biomedical Sciences, Drug Discovery +6

The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro et al. · Annals of Oncology · 2021 · 262 citations · Full text

Medicine, Oncology, Pharmacotherapy +13